• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Evaluation of the validity of Ag PANBIO-COVID19 in the diagnosis of SARS-CoV-2 infection in asymptomatic or mildly infected patients].[评估Ag PANBIO - COVID19在无症状或轻度感染患者中诊断新型冠状病毒感染的有效性]
Rev Esp Quimioter. 2021 Dec;34(6):618-622. doi: 10.37201/req/054.2021. Epub 2021 Sep 22.
2
The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan.一种新型抗原检测试剂(QuickNavi™-COVID19 Ag)用于 SARS-CoV-2 的评估:日本的一项前瞻性观察研究。
J Infect Chemother. 2021 Jun;27(6):890-894. doi: 10.1016/j.jiac.2021.02.029. Epub 2021 Mar 4.
3
Screening for SARS-CoV-2 infection in asymptomatic individuals using the Panbio COVID-19 antigen rapid test (Abbott) compared with RT-PCR: a prospective cohort study.使用 Panbio COVID-19 抗原快速检测试剂盒(Abbott)与 RT-PCR 相比,对无症状个体进行 SARS-CoV-2 感染筛查:一项前瞻性队列研究。
BMJ Open. 2021 Oct 13;11(10):e048206. doi: 10.1136/bmjopen-2020-048206.
4
The Panbio COVID-19 Ag Rapid Test: Which Performances are for COVID-19 Diagnosis?攀迪 COVID-19 Ag 快速检测试剂:哪些性能可用于 COVID-19 诊断?
Clin Lab. 2021 Nov 1;67(11). doi: 10.7754/Clin.Lab.2021.210304.
5
Prospective analytical performance evaluation of the QuickNavi™-COVID19 Ag for asymptomatic individuals.无症状个体的 QuickNavi™-COVID19 Ag 前瞻性分析性能评估。
J Infect Chemother. 2021 Oct;27(10):1489-1492. doi: 10.1016/j.jiac.2021.07.005. Epub 2021 Jul 9.
6
Thoracic imaging tests for the diagnosis of COVID-19.用于诊断新型冠状病毒肺炎的胸部影像学检查
Cochrane Database Syst Rev. 2020 Sep 30;9:CD013639. doi: 10.1002/14651858.CD013639.pub2.
7
Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients.评估一种用于检测 COVID-19 患者无症状密切接触者中 SARS-CoV-2 的快速抗原检测(Panbio™ COVID-19 Ag 快速检测设备)。
Clin Microbiol Infect. 2021 Apr;27(4):636.e1-636.e4. doi: 10.1016/j.cmi.2020.12.022. Epub 2021 Jan 6.
8
"The effectiveness of rapid antigen test-based for SARS-CoV-2 detection in nursing homes in Valencia, Spain".《西班牙巴伦西亚养老院基于快速抗原检测的 SARS-CoV-2 检测效果》。
J Clin Virol. 2021 Oct;143:104941. doi: 10.1016/j.jcv.2021.104941. Epub 2021 Aug 10.
9
Performance evaluation of an automated SARS-CoV-2 Ag test for the diagnosis of COVID-19 infection on nasopharyngeal swabs.基于鼻咽拭子的自动化 SARS-CoV-2 Ag 检测用于 COVID-19 感染诊断的性能评估。
Clin Chem Lab Med. 2021 Jul 30;59(12):2003-2009. doi: 10.1515/cclm-2021-0569. Print 2021 Nov 25.
10
Real-life evaluation of a COVID-19 rapid antigen detection test in hospitalized children.在院儿童中 COVID-19 快速抗原检测的真实世界评估。
J Med Virol. 2021 Oct;93(10):6040-6044. doi: 10.1002/jmv.27149. Epub 2021 Jul 1.

本文引用的文献

1
Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection.用于诊断 SARS-CoV-2 感染的 CerTest 和 Panbio 抗原快速诊断检测的诊断性能。
J Clin Virol. 2021 Apr;137:104781. doi: 10.1016/j.jcv.2021.104781. Epub 2021 Feb 21.
2
Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection.用于诊断严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的Panbio™新冠病毒快速抗原检测试验的多中心评估
Clin Microbiol Infect. 2021 Feb 16;27(5):758-61. doi: 10.1016/j.cmi.2021.02.001.
3
Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care.Panbio™ 快速抗原检测 SARS-CoV-2 在初级保健中有症状患者中具有可接受的准确性。
J Infect. 2021 Mar;82(3):391-398. doi: 10.1016/j.jinf.2021.02.014. Epub 2021 Feb 13.
4
Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection.Panbio™ COVID-19抗原快速检测(雅培公司)在有潜在SARS-CoV-2感染症状的社区居民中的实际应用验证
EClinicalMedicine. 2021 Jan;31:100677. doi: 10.1016/j.eclinm.2020.100677. Epub 2020 Dec 5.
5
Limits and Opportunities of SARS-CoV-2 Antigen Rapid Tests: An Experienced-Based Perspective.严重急性呼吸综合征冠状病毒2抗原快速检测的局限性与机遇:基于经验的视角
Pathogens. 2021 Jan 5;10(1):38. doi: 10.3390/pathogens10010038.
6
Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients.评估一种用于检测 COVID-19 患者无症状密切接触者中 SARS-CoV-2 的快速抗原检测(Panbio™ COVID-19 Ag 快速检测设备)。
Clin Microbiol Infect. 2021 Apr;27(4):636.e1-636.e4. doi: 10.1016/j.cmi.2020.12.022. Epub 2021 Jan 6.
7
Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms.Panbio 抗原快速检测在症状出现后 7 天内对诊断 SARS-CoV-2 感染是可靠的。
J Clin Virol. 2020 Dec;133:104659. doi: 10.1016/j.jcv.2020.104659. Epub 2020 Oct 16.
8
Evaluation of the Panbio COVID-19 Rapid Antigen Detection Test Device for the Screening of Patients with COVID-19.用于筛查新型冠状病毒肺炎患者的Panbio新型冠状病毒肺炎快速抗原检测试剂盒的评估
J Clin Microbiol. 2021 Jan 21;59(2). doi: 10.1128/JCM.02589-20.
9
Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings.第二波疫情期间抗原检测在急性SARS-CoV-2感染诊断中的应用建议:不同临床环境下的态度
Rev Esp Quimioter. 2020 Dec;33(6):466-484. doi: 10.37201/req/120.2020. Epub 2020 Oct 19.
10
Potential Trends of Point-of-Care Diagnostics-The Next Generation of the Laboratory Diagnosis.
Diagnostics (Basel). 2020 Sep 30;10(10):774. doi: 10.3390/diagnostics10100774.

[评估Ag PANBIO - COVID19在无症状或轻度感染患者中诊断新型冠状病毒感染的有效性]

[Evaluation of the validity of Ag PANBIO-COVID19 in the diagnosis of SARS-CoV-2 infection in asymptomatic or mildly infected patients].

作者信息

Gras-Valenti P, Vidal I, Montiel-Higuero I, Escribano I, Algado-Selles N, Chico-Sánchez P, Ventero M P, Jiménez-Sepulveda N, Molina-Pardines C, Merino-Lucas E, Sánchez-Payá J, Rodríguez J C

机构信息

Maria Paz Ventero Martín. Hospital General Universitario de Alicante, C/Pintor Baeza, 12. CP:03010. Spain.

出版信息

Rev Esp Quimioter. 2021 Dec;34(6):618-622. doi: 10.37201/req/054.2021. Epub 2021 Sep 22.

DOI:10.37201/req/054.2021
PMID:34549577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8638769/
Abstract

OBJECTIVE

To assess the validity of SARS-CoV-2 Antigen (Ag) detection for the diagnosis of SARS-CoV-2 infection in mildly infected or asymptomatic patients.

METHODS

Observational study to evaluate diagnostic tests. Non-hospitalized patients with indication for diagnostic testing for SARS-CoV-2 infection were included. The diagnostic test to be evaluated was the determination of Ag and as a reference standard to determine the presence of viral RNA the RT-PCR was used.

RESULTS

A total of 494 patients were included. Of these 71.5% (353/494) had symptoms and 28.5% (141/494) were asymptomatic (presurgery screening (35/494) and confirmed case-contact (106/494). The overall sensitivity of the Ag test was 61.1% and the specificity was 99.7%. The sensitivity and specificity in the asymptomatic group were 40% and 100% respectively, and in the symptomatic group 63.5% and 99.6% respectively. In turn, the sensitivity and specificity in the group of symptomatic patients varied according to the time of symptom evolution: in patients with recent symptoms, they were 71.4% and 99.6% respectively, while in patients with symptoms of more than 5 days of evolution, they were 26.7% and 100% respectively. In all groups studied, the presence of antigen is associated with a high viral load (Ct<30 cycles).

CONCLUSIONS

The use of Ag detection test is not indicated for the diagnosis of SARS-CoV-2 infection in asymptomatic patients or with symptoms of more than 5 days of evolution, but it could be useful in patients with symptoms of 1-5 days of evolution.

摘要

目的

评估严重急性呼吸综合征冠状病毒2(SARS-CoV-2)抗原(Ag)检测用于诊断轻度感染或无症状患者SARS-CoV-2感染的有效性。

方法

进行观察性研究以评估诊断检测。纳入有SARS-CoV-2感染诊断检测指征的非住院患者。待评估的诊断检测为Ag测定,以逆转录聚合酶链反应(RT-PCR)作为确定病毒RNA存在的参考标准。

结果

共纳入494例患者。其中71.5%(353/494)有症状,28.5%(141/494)无症状(术前筛查(35/494)和确诊病例接触者(106/494))。Ag检测的总体敏感性为61.1%,特异性为99.7%。无症状组的敏感性和特异性分别为40%和100%,有症状组分别为63.5%和99.6%。反过来,有症状患者组的敏感性和特异性根据症状演变时间而有所不同:近期有症状的患者分别为71.4%和99.6%,而症状演变超过5天的患者分别为26.7%和100%。在所有研究组中,抗原的存在与高病毒载量(Ct<30个循环)相关。

结论

Ag检测试验不适用于诊断无症状患者或症状演变超过5天的患者的SARS-CoV-2感染,但对症状演变1-5天的患者可能有用。